Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Burke

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
JHEP Reports : Innovation in Hepatology|December 13, 2023
Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care deliveryNadir Abbas, Rachel Smith, Steven Flack, et al.
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Plos One|January 10, 2013
On the interplay of telomeres, nevi and the risk of melanomaClara Bodelon, Ruth M Pfeiffer, Valentina Bollati, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
JHEP Reports : Innovation in Hepatology|December 13, 2023
Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care deliveryNadir Abbas, Rachel Smith, Steven Flack, et al.
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Plos One|January 10, 2013
On the interplay of telomeres, nevi and the risk of melanomaClara Bodelon, Ruth M Pfeiffer, Valentina Bollati, et al.
Pageof 4